The PESCO study evaluated MVP-S with pembrolizumab and low-dose cyclophosphamide in recurrent epithelial ovarian cancer.
What was announced
BioVaxys reported positive preliminary results from the investigator-initiated Phase 1B/2 PESCO study in recurrent epithelial ovarian cancer.
The open-label, non-randomized trial evaluates MVP-S in combination with pembrolizumab and low-dose cyclophosphamide.
BioVaxys highlighted a study subject who remained in complete response for three years and said the findings exceeded expectations compared with standard single-agent chemotherapy in platinum-resistant disease.
Source
Read the complete issuer announcement and supporting public materials for full context, assumptions and risk information.
View original source ↗Cornerstone Marketing Inc. provides paid digital media, marketing and news-dissemination services for certain issuers featured in this newsroom. This article is informational and is not investment advice or a recommendation to buy or sell securities.
Read the complete disclosure →